Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00424632 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
57
Enrollment target
2
Study locations

NCT00424632: Completed Phase 1 study of Solid Tumors, sponsored by Pfizer.

NCT00424632 is a Phase 1 study of Solid Tumors that has completed, run by Pfizer. The registered enrollment target is 57 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00424632, a Phase 1 study of Solid Tumors, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
57 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of PF-03814735 administered orally as single agent in patients with advanced solid tumors.

Primary Outcome

DLT defined as any of the following during the first cycle of treatment and attributable to PF-03814735: Grade (Gr) 4 neutropenia (absolute neutrophil count \[ANC\] \<500 cells/mm\^3) for \>7 days or febrile neutropenia (ANC \<1000/mm\^3, fever ≥38 degrees Celsius; neutropenic infection (ANC \<1000/mm\^3); Gr 4 thrombocytopenia (platelets \<25,000 cells/mm\^3); ≥Gr 3 nausea, vomiting, or diarrhea, despite optimal antiemetic, anti-diarrheal support; ≥20% decrease in left ventricular ejection frac

Conditions Studied

Solid Tumors

Interventions

  • DRUG PF-03814735

Study Locations (2)

Tennessee

  • Pfizer Investigational Site - Nashville

Other

  • Pfizer Investigational Site - Leuven

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2006-11
Est. Completion 2009-06
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT00424632 record still lists

NCT00424632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which PF-03814735 is the first listed.

NCT00424632 reports a single indexed study location in Tennessee, Other.

Frequently Asked Questions

What is clinical trial NCT00424632 about?

NCT00424632 is a clinical study titled "Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors". The purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of PF-03814735 administered orally as single agent in patients with advanced solid tumors.

What is the current status of trial NCT00424632?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2006-11. Estimated completion is 2009-06.

What conditions does trial NCT00424632 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT00424632?

The interventions under investigation include: PF-03814735 (DRUG).

Who is sponsoring clinical trial NCT00424632?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00424632 being conducted?

This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00424632's enrollment target sits among peer trials

57 77th of 125 higher than 49 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03521830 · 57 participants · Phase 2

    Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

  • NCT03587701 · 57 participants · Phase 2

    Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

  • NCT04104126 · 57 participants · NA

    Blood Flow Restriction Therapy in Achilles Injury

  • NCT04703842 · 57 participants · Phase 1

    Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00424632, the US trial registry maintained by the National Library of Medicine. NCT00424632 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.